Search PubMed⌕ Search

Biomedical subjects

M A Omar

Publications and source records attributed to M A Omar.

At least 37 records · Page 2Linked to original sources
PubMed1995

Rapid surveys in support of district health information systems: an experience from Uganda.

The role of rapid health assessment in generating data other than routine reporting for a multi-element primary health care information system is presented. Rapid surveys, based on the adaptation of the WHO/EPI cluster survey methodology, may generate reliable and valid results useful for the support of a managerial PHC information system. However, because of the limitations inherent to the method, so far, only few studies have investigated more than few PHC related issues. The experience of a household rapid survey conducted in Arua District, Uganda, using a modified EPI cluster survey methodology, is reported. Rapid appraisal methods were used to prioritize the information requirement and to identify the survey items. Fully supervised teams of primary school teachers were used as interviewers. Data processing, check and analysis were speeded up by a lap-top computer, in spite of problems of erratic power. Within a 10-day time span between the start of the survey and the publishing of results, data on health services' utilization, health seeking behaviour, coverage of PHC services, including immunization, and anthropometric data on the nutritional status of under-five children were obtained. Standard errors and 95% confidence intervals were calculated taking into account the variability of the parameters under investigation and true design effects were computed. The findings were utilized for the identification of health priorities and the monitoring of effectiveness of programmes, as well as to validate routine reporting. The methodological package was built up looking at the local context, so that it could become an operational tool for the district health management team.

Adolescent↗
PubMed1994

Evaluation of WHO and NDDG criteria for impaired glucose tolerance.

A 4-year prospective study on the natural history of IGT in South African Indians has allowed for the evaluation of the WHO and NDDG criteria for IGT, using the five groups for non-diabetic glucose tolerance recently recommended and relating these to the risk of diabetes development. Using WHO criteria, 128 subjects were classed IGT in a baseline survey (Year 0). The five recommended categories were applied to the OGTTs done between Year 1 and Year 4 of the study, when mid-test plasma (MPG) samples were also obtained. These categories included N-N (Normal by WHO and NDDG); N-ND1 (Normal by WHO, non-diagnostic level 1 by NDDG); N-ND2 (Normal by WHO, non-diagnostic level 2 by NDDG); I-ND3 (IGT by WHO, non-diagnostic level 3 by NDDG) and I-I (IGT by WHO and NDDG). The risk of diabetes development and the significance of the non-diagnostic category were evaluated by comparing the glucose tolerance status at Year 4 with the status at Year 1. In the cross-sectional evaluation at Year 1, of the 87 non-diabetic OGTTs analysed, 31% (n = 27) were classified I-I, 34.5% (n = 30) were classed N-N and 34.5% (n = 30) were classified non-diagnostic [I-ND3 (23.1%); N-ND2 (8%); N-ND1 (3.4%)]. In the prospective analysis, of the 72 subjects who completed the study, 16 subjects developed NIDDM by Year 4; of these 13 subjects were classed I-I and 3 subjects I-ND3 at Year 1.(ABSTRACT TRUNCATED AT 250 WORDS)

Blood Glucose↗
PubMed1994

Evidence for impaired pancreatic beta cell function in South African Indians with impaired glucose tolerance.

In a prospective study of South African Indians with impaired glucose tolerance (IGT), the serum insulin response during a 75 g oral glucose tolerance test (OGTT) was examined in 128 subjects who were classified as IGT 1 year previously (year 0) and in 60 matched control subjects. Based on the results at year 1, study subjects were divided into three groups, using World Health Organization criteria for glucose tolerance: IGT (n = 47), diabetes (n = 41), and transient IGT (normal glucose tolerance) (n = 40). When compared with the control group, despite higher plasma glucose concentrations, the IGT group showed similar fasting insulin, but lower 30-min insulin response (57.4 +/- 1.9 mUl-1 vs 86.5 +/- 1.8, p < 0.001) and lower 30-min insulin/glucose ratio (7.4 +/- 5.2 vs 13.3 +/- 8.7, p < 0.001). The insulinogenic index was lower in the IGT group than in the control group at 30, 60, 90, and 120 min (p < 0.01, p < 0.001, p < 0.001, p < 0.001, respectively). The 2-h insulin response was higher in the IGT group (106.7 +/- 1.9 mUl-1 vs 59.2 +/- 1.9, p < 0.01). The IGT group displayed a delayed pattern of insulin response with maximum levels only at 2-h. Insulin area was similar in the two groups. In the transient IGT group, despite similar plasma glucose levels, the insulin responses at 0, 15, 30, and 60 min (p < 0.01, p < 0.001, p < 0.001, p < 0.001, respectively) were lower than in the control group; the 30-min insulin/glucose ratio (7.1 +/- 5.1 vs 13.3 +/- 8.7, p < 0.001) and 60-min insulinogenic index (46.9 +/- 86.3 vs 123.4 +/- 206.3, p < 0.001) were also lower in the transient IGT group.(ABSTRACT TRUNCATED AT 250 WORDS)

Adult↗
PubMed1994

South African Indians show a high prevalence of NIDDM and bimodality in plasma glucose distribution patterns.

OBJECTIVE: To determine the prevalence of diabetes mellitus and impaired glucose tolerance (IGT) and to test for bimodality in the plasma glucose distribution in South African Indians. RESEARCH DESIGN AND METHODS: Subjects were selected by systematic cluster sampling in various areas of Durban. They underwent a modified glucose tolerance test whereby fasting and 2-h postglucose (75 g) plasma glucose levels were measured. The program MIX was used to test for bimodality in the plasma glucose distribution. RESULTS: We tested 2,479 subjects (1,441 women and 1,038 men). Based on the revised World Health Organization criteria, the crude prevalence of diabetes mellitus was 9.8%, and the crude prevalence of IGT was 5.8%; the age- and sex-adjusted prevalence was 13.0 and 6.9%, respectively. IGT was significantly more common in men (7.6%) than in women (4.4%). Obesity was a feature of both diabetes mellitus and IGT, particularly in women. Both fasting and 2-h plasma glucose values did not conform to a single normal distribution pattern in any age-group, whereas unequivocal evidence of bimodality was seen in the 55- to 74-year age-group of both sexes for fasting and 2-h glucose and also in the 2-h levels of men in the 25- to 34-year age-group. CONCLUSIONS: This study has highlighted a high prevalence of non-insulin-dependent diabetes mellitus in South African Indians and bimodality in the plasma glucose distribution.

Adolescent↗
PubMed1994

The district health information system and its potential in the management of district and rural hospitals.

A study to assess the role that the HIS plays in the management of district and rural hospitals in Zvimba district (Zimbabwe) was carried out by the authors between August and October 1993. It revealed that there is an elaborate and well-developed set of tools which mainly collect data on morbidity, mortality, births, coverage and health activities. Cost and financial data as well as community-based data are not entering the HIS at the peripheral level. Very little analysis and interpretation of data takes place at the rural and district hospitals, therefore limiting the indicators that could be derived. Staff use the raw data they collect mostly for patient care. In terms of processed data, there is little use made of it.

Community Health Services↗
PubMed1993

High risk of progression to NIDDM in South-African Indians with impaired glucose tolerance.

A four-yr prospective study was undertaken to examine the natural history of IGT in 128 South-African Indians classified as such at year 0 of the study, based on WHO criteria. Subjects were reexamined at year 1 and year 4. Of the 113 subjects who completed the study, 50.4% progressed to NIDDM (rate of progression 12.6%/yr), 24.8% persisted with IGT, and 24.8%, reverted to NGT. The majority (72%) who progressed to NIDDM did so in year 1. At year 1, 47 subjects were still classified as IGT; of the 40 subjects completing the study, 16 subjects (40%) progressed to NIDDM, 17 subjects (42.5%) persisted with IGT, and 7 subjects (17.5%) reverted to NGT. Examination of risk factors predictive of subsequent progression to NIDDM was undertaken by analysis of baseline variables in two ways: When year 0 was used as baseline (in 113 IGT0 subjects), significant predictive risk factors were the FPG and 2-h plasma glucose concentrations. All subjects who at year 0 had 2-h plasma glucose > or = 10.2 and < 11.1 mM or FPG > or = 7.3 but < 7.8 mM, subsequently progressed to NIDDM. When year 1 was used as baseline (40 IGT1 subjects), 90-min plasma glucose concentration (midtest level) was found to be a significant risk factor for development of NIDDM. In conclusion, this study has demonstrated that in South-African Indians with IGT, the majority (50.4%) progress to NIDDM within 4 yr; significant predictors of subsequent diabetes are the baseline fasting and 2-h plasma glucose concentration.(ABSTRACT TRUNCATED AT 250 WORDS)

Analysis of Variance↗
PubMed1993

Selected risk factors for coronary heart disease in male scholars from the major South African population groups.

A number of risk factors for coronary heart disease (CHD) in 7 groups of South African male scholars aged between 15 and 20 years were surveyed. Selection of the groups was based on socioeconomic status and comprised urban and rural blacks, Indians of higher and lower socio-economic status, coloureds of higher and lower socioeconomic status, and middle-class whites. Both Indian groups, both coloured groups and the whites had a much greater prevalence and severity of CHD risk factors than the two black groups. This held for total cholesterol, low-density lipoprotein cholesterol (LDLC), high-density lipoprotein cholesterol (HDLC), the HDLC/LDLC ratio, apolipoprotein B, apolipoprotein A-I, insulin, fibrinogen and mass. One exception was lipoprotein a, levels of which were higher in both black groups. In general the CHD risk factor profile was worse in the higher socio-economic groups, and it also tended to be worse in urban than in rural blacks. These findings stress the need to reduce CHD risk factors in our developed populations and to prevent their emergence in our developing peoples.

Adolescent↗
PubMed1993

Vaginal yeast infections in diabetic women.

Two hundred and three diabetic women (89 with and 114 without genital symptoms) were examined for the presence of yeasts and Trichomonas vaginalis. Yeasts were isolated from the vaginas of 35.5% of patients and were more common in the symptomatic group (48.0%) than the asymptomatic group (25.4%; P < 0.05). Candida albicans was isolated from 12.8% of all patients and showed a significant association with pruritus vulvae (P < 0.05). A significant association was also shown between the presence of yeasts in the rectum and in the vagina. C. glabrata (Torulopsis glabrata) was the commonest yeast species isolated (50.0%), with C. albicans the next most frequent (36.1%). T. vaginalis infection was present in 14.3% of all subjects.

Adolescent↗
PubMed1993

The prevalence of diabetes mellitus and impaired glucose tolerance in a group of urban South African blacks.

The prevalence of diabetes mellitus and impaired glucose tolerance (IGT) was determined in 479 urbanised South African blacks (141 men and 338 women) of Zulu descent selected by cluster sampling in a suburb of Durban. All subjects underwent a modified glucose tolerance test whereby fasting and 2-hour post-glucose (75 g) plasma glucose levels were measured. On the basis of the revised World Health Organisation criteria, the overall prevalence of diabetes was 4.2% and of IGT 6.9%; the age- and sex-adjusted prevalences were 5.3% and 7.7% respectively. Diabetes mellitus was more common in women (5.2% v. 2.3%), while the reverse was true of IGT (5.5% v. 11.5%). The mean age-adjusted body mass indices (BMIs) of diabetic (31.3 +/- 1.9) and IGT (29.7 +/- 1.9) subjects were significantly higher than those of the group with normal glucose tolerance (28 +/- 0.5). Female subjects with all types of glucose tolerance had significantly higher mean BMIs than men. There was a significant correlation between BMI and both fasting glucose (r = 0.16; P = 0.0039) and 2-hour plasma levels (r = 0.15; P = 0.0065) in the women, while in men only the fasting levels showed such a relationship (r = 0.21; P = 0.01719).

Adolescent↗
PubMed1992

The value of glycosylated haemoglobin as a substitute for the oral glucose tolerance test in the detection of impaired glucose tolerance (IGT).

In a prospective study of South African Indian subjects with IGT, glycosylated hemoglobin [specifically HbA1 (HbA1(a+b+c)] and its relationship to the oral glucose tolerance test (OGTT) was studied in 128 study subjects who were classified IGT a year previously (Year 0 of study) and in 64 control subjects. At Year 1 of the study, the standard 75-g OGTT was performed on all subjects; study subjects were further divided into three groups based on World Health Organisation criteria [Normal (N), impaired glucose tolerance (IGT), diabetes mellitus (D)]. HbA1, a glycosylated hemoglobin (GHb), was measured by a cation-exchange microchromatographic method. Based on OGTT results, 47 of the 128 study subjects were classified IGT, 41 diabetes (newly-diagnosed diabetes) and 40 subjects had normal glucose tolerance. Mean GHb was significantly higher in the D group (7.61 +/- 1.76%) compared to the control group (6.99 +/- 1.22%) and the N group (6.9 +/- 1.12%), respectively (P less than 0.05); there was no significant difference between the IGT group (7.48 +/- 1.44%) and each of the other three groups. Compared to the OGTT, GHb was relatively insensitive in the diagnosis of IGT or diabetes mellitus: only 17% of the IGT group and 26.8% of the D group has elevated GHb values; the specificity of GHb as a measure of normal glucose tolerance was 85.9%. The majority of subjects, irrespective of the category of glucose tolerance, had GHb levels within the normal range and there was marked overlap between the four groups.(ABSTRACT TRUNCATED AT 250 WORDS)

Adolescent↗
PubMed1992

Effect of insulin therapy on blood pressure in NIDDM patients with secondary failure.

OBJECTIVE: To assess the effect of insulin therapy on blood pressure in NIDDM patients with secondary failure. RESEARCH DESIGN AND METHODS: The influence of insulin treatment on blood pressure was assessed retrospectively in a group of 80 NIDDM patients with secondary failure to diet and maximum doses of oral hypoglycemic agents. Weight, blood glucose, and blood pressure were recorded over a 3-mo period before and after the initiation of insulin therapy. RESULTS: There was a significant rise in systolic (131.8 +/- 1.7 to 148 +/- 1.9 mmHg, P less than 0.05) and diastolic (80.9 +/- 0.9 to 89.2 +/- 1.0 mmHg, P less than 0.02) blood pressures with insulin treatment. Insulin treatment was associated with a significant decrease in blood glucose (18.36 +/- 0.28 to 10.4 +/- 0.34 mM, P less than 0.01) and an increase in weight (72.1 +/- 1.6 to 78 +/- 1.7 kg, P = 0.01). A control group of 80 NIDDM patients matched for age, weight, BMI, and duration of diabetes demonstrated no significant change in blood pressure over a matched period of follow-up. CONCLUSIONS: This study has shown that insulin therapy is associated with significant elevation of both systolic and diastolic blood pressures.

Blood Glucose↗
PubMed1992

Simvastatin in non-insulin-dependent diabetic patients with hypercholesterolaemia.

The objective of this study was to evaluate the lipid-lowering effect of simvastatin in non-insulin-dependent diabetes mellitus (NIDDM) patients with hypercholesterolaemia while possible clinical and biochemical adverse effects were monitored for. Forty-three NIDDM patients with hypercholesterolaemia (total cholesterol > 6.5 mmol/l) used simvastatin after a detailed clinical laboratory evaluation as well as a 4-week wash-out period and a 4-week placebo baseline period. Simvastatin treatment was initiated with a 10 mg dose for 6 weeks; this was increased to 20 mg and 40 mg at 12 and 18 weeks of follow-up respectively if the total cholesterol level had not decreased to below 5.17 mmol/l. Patients were placed on a lipid-lowering diet and continued to take any regular non-lipid-lowering medication throughout the trial; side-effects were monitored at 6-week intervals until patients had taken simvastatin for 24 weeks. The mean total cholesterol level was reduced by 22.2% at the first follow-up visit, and by 24.2%, 23.3%, and 28.5% at the second, third and fourth follow-up visits respectively compared with base-line levels. A dose of 10 mg simvastatin brought about a reduction in total cholesterol similar to those found with higher doses. The mean triglyceride level was reduced by 20.9% with 20 mg simvastatin. The high-density lipoprotein cholesterol level was not altered significantly and neither was the control of diabetes.(ABSTRACT TRUNCATED AT 250 WORDS)

Adult↗
PubMed1992

Health care for nomads too, please.

Pastoral nomadism, a way of life in many developing countries, especially in Africa, has received little attention from planners, economists and governments, partly because the communities in question present what are perceived as difficult logistical problems. Yet it is incumbent on the authorities to develop practical and feasible approaches to the delivery of primary health care for nomadic populations.

Africa↗
PubMed1991

A 6-month trial of simvastatin (HMG-CoA reductase inhibitor) in the treatment of hypercholesterolaemia.

The aim of this study was to evaluate the long-term efficacy and tolerability of the 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor simvastatin, over a 24-week period. Patients (108) with primary hypercholesterolaemia were clinically, haematologically and biochemically evaluated and established on a cholesterol-lowering diet. After a wash-out period free from other lipid-lowering drugs and a baseline period on placebo of 1 month each, 10 mg simvastatin was introduced at night. The dose was increased to 20 mg and 40 mg at 6 and 12 weeks' follow-up respectively if the total cholesterol (TC) level was still above 5.17 mmol/l. Follow-up took place every 6 weeks and included lipid, haematological, biochemical and clinical evaluation. A full ophthalmological evaluation was conducted at baseline and at 24 weeks' follow-up. Overall the TC level was reduced below the baseline level by 34.3% at week 18 of follow-up and 32.5% at week 24. Patients with higher initial TC levels showed greater TC lowering in response to simvastatin than did those with lower initial TC levels. A group of 45 patients was followed up for an additional 12 weeks after the end of the trial and maintained TC reductions similar to those at the end of the trial. Fourteen patients experienced adverse effects which were thought to be drug-related. One patient was withdrawn from the trial after developing conjunctivitis that proved to be related to the use of simvastatin.(ABSTRACT TRUNCATED AT 250 WORDS)

Adolescent↗